Consensus Kura Oncology, Inc.

Equities

KURA

US50127T1097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
18.75 ^USD	0.00%		+4.22%	+30.39%

Apr. 22	Sector Update: Health Care Stocks Advance Premarket Monday	MT
Apr. 22	Kura Oncology Gets Breakthrough Designation For Leukemia Therapy	DJ

Evolution of the average Target Price on Kura Oncology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

db69045d5b1.KlwTSCP5ENzlTWKt0A9Ti_aNlhO60tQYq_npwBpvQ8w.HAZWHXC4PaWGADvPu04p5JvAwHbuvoJxmdS5uSMDdo4bMUQ8bMhxiI1-Wg~7313683ac54f17f36e7c6926a241ffd2

Analyst Recommendations on Kura Oncology, Inc.

Mizuho Securities Initiates Kura Oncology With Buy Rating, Price Target is $26	Dec. 22	MT
Wedbush Lowers Kura Oncology's PT to $37 From $40, Adjusts Valuation, Market Assumptions After Q3 Results; Keeps Outperform Rating	Nov. 03	MT
Kura Oncology Says Tipifarnib Shows Overall Response Rate of 30%, 20% in Assessments for Squamous Cell Carcinoma	23-10-17	MT
BofA Securities Initiates Coverage on Kura Oncology with Buy Rating, $31 Price Target	23-08-11	MT
Scotiabank Starts Kura Oncology at Sector Perform With $10.50 Price Target	23-07-27	MT
Stifel Adjusts Price Target on Kura Oncology to $25 From $24, Maintains Buy Rating	23-06-12	MT
BTIG Initiates Kura Oncology at Buy With $31 Price Target	23-05-17	MT
Stifel Starts Kura Oncology at Buy With $25 Price Target	23-01-31	MT
Credit Suisse Raises Kura Oncology's PT to $29 from $27 to Reflect Changes to Market Model, Point of Sale for Ziftomenib; Maintains Outperform Rating	22-07-13	MT
Cantor Fitzgerald Initiates Coverage on Kura Oncology With Overweight Rating, $30 Price Target	22-07-12	MT
SVB Leerink Lowers Kura Oncology's Price Target to $28 From $41, Maintains Outperform Rating	22-02-25	MT
Credit Suisse Lifts Kura Oncology's Price Target to $27 from $25, Notes Rich Catalyst Lineup Into H2; Keeps Outperform Rating	22-02-25	MT
Jefferies Financial Initiates Kura Oncology at Buy, Sets Price Target at $35	22-02-15	MT
Credit Suisse Lifts Kura Oncology's Price Target to $25 from $21, Maintains Outperform Rating	22-02-14	MT
Kura Oncology Reports 56% Overall Response Rate in T-Cell Lymphoma Drug Study	21-12-13	MT
Credit Suisse Adjusts Kura Oncology's Price Target to $21 From $40, Keeps Outperform Rating	21-11-26	MT
HC Wainwright Adjusts Price Target on Kura Oncology to $32 From $43, Maintains Buy Rating	21-11-24	MT
Wedbush Cuts Kura Oncology's Price Target to $40 From $53 After KO-539 Partial Clinical Hold; Outperform Rating Kept	21-11-24	MT
KURA ONCOLOGY : Credit Suisse Lowers Kura Oncology's PT to $40 from $42, Updates Model with Q2 Actuals, Adjusts KO-539 Launch Trajectory Assumptions; Keeps Outperform Rating	21-08-06	MT
KURA ONCOLOGY : SVB Leerink Adjusts Price Target on Kura Oncology to $40 From $42, Maintains Outperform Rating	21-02-26	MT
KURA ONCOLOGY : Wedbush Adjusts Kura Oncology's Price Target to $53 From $56, Keeps Outperform Rating	21-02-25	MT
KURA ONCOLOGY : HC Wainwright Adjusts Kura Oncology's Price Target to $43 from $45, Keeps Buy Rating	21-02-24	MT
KURA ONCOLOGY : Barclays Adjusts Kura Oncology PT to $47 From $40, Maintains Overweight Rating	20-12-07	MT
KURA ONCOLOGY : HC Wainwright Adjusts Kura Oncology's Price Target to $45 From $40, Keeps at Buy	20-12-07	MT
KURA ONCOLOGY : Wedbush Adjusts Kura Oncology's Price Target to $56 From $44 on KO-539/AML Data; Outperform Rating Kept	20-12-07	MT